Clinical Correlates Of Sleep Problems In Systemic Sclerosis: The Prominent Role Of Pain PDF Print E-mail
Sunday, 16 January 2011 21:39
Objective. Problems with sleep are common in patients with SSc and impact daily function. Little research, however, has examined factors associated with sleep disruption in SSc. Therefore, the objective of this study was to investigate socio-demographic and medical factors associated with sleep disruption in SSc.

Methods. Cross-sectional study of 70 patients from one Canadian Scleroderma Research Group site who were assessed with a 100-mm sleep disruption visual analogue scale (VAS). Patients also completed measures of pain and depressive symptoms and underwent clinical histories and medical examinations. Pearson’s correlations were used to assess bivariate association of socio-demographic and medical variables with sleep VAS scores. Multivariable associations of socio-demographic (Step 1) and medical (Step 2) variables with sleep VAS scores were assessed using hierarchical multiple linear regression.

Results. The mean (S.D.) sleep disruption VAS score was 38.5 (29.9). In bivariate analyses, sleep disruption was associated with marital status (r =0.24, P = 0.042), smoking (r = 0.27, P = 0.025), gastrointestinal symptoms (r = 0.27, P = 0.023), breathing problems (r = 0.31, P = 0.009), pain (r = 0.53, P<0.001) and symptoms of depression (r = 0.34, P = 0.004). In multivariate analysis, only marital status (standardized  =0.24, P = 0.049) and pain (standardized  = 0.50, P<0.001) were significantly associated with sleep disruption.

Conclusion. Sleep disruption scores were as high in SSc as in RA and higher than in the general population. Pain was robustly associated with sleep disruption. Additional research is needed on sleep in SSc so that well-informed sleep interventions can be developed and tested.

Login to download your own copy of the full and original article from the link provided below

 
More articles :

» Pulsed High-Dose Corticosteroids Combined With Low-Dose Methotrexate in Severe Localized Scleroderma

Alexander Kreuter, MD; Thilo Gambichler, MD; Frank Breuckmann, MD; Sebastian Rotterdam, MD; Marcus Freitag, MD; Markus Stuecker, MD; Klaus Hoffmann, MD; Peter Altmeyer, MDArch Dermatol. 2005;141:847-852Objective: To evaluate the efficacy of pulsed...

» Pathogenesis and Therapeutic Approaches for Improved Topical Treatment in Localized Scleroderma and Systemic Sclerosis

I. Badea; M. Taylor; A. Rosenberg; M. FoldvariPosted: 09/03/2009; Rheumatology. 2009;48(3):213-221. © 2009 Oxford University PressSSc is a chronic progressive disorder of unknown aetiology characterized by excess synthesis and deposition of...

» Could The Drug Gleevec Be The First Possible Treatment For Scleroderma?

Investigators have identified a drug that is currently approved to treat certain types of cancer, , that could provide the first treatment for . The news will be presented at the annual meeting of the on October 18 in Philadelphia. "There has never...

» Stem Cell Transplant Helps Retired New Jersey Principal

Covered within a recent article, New Jersey resident, Michael George feels “reborn” after having his own implanted in him to treat his in a new . The retired William C. McGinnis School principal, who in April was taken off all medications,...

» The Imbalanced Expression of Matrix Metalloproteinases in Nephrogenic Systemic Fibrosis

Brent C. Kelly, MD, Leslie Scroggins Markle, MD, Jennifer L. Vickers, MD, Matthew S. Petitt, DO, Sharon S. Raimer, MD, and Catherine McNeese, MDBackground: Nephrogenic systemic fibrosis (NSF) occurs in patients with renal dysfunction and gadolinium...

» What is Chelation Therapy?

Chelation (pronounced key-LAY-shun) therapy is a chemical process in which a synthetic solution-EDTA (ethylenediaminetetraacetic acid) is injected into the bloodstream to remove heavy metals and/or minerals from the body. Chelation means "to grab"...